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Abstract The aim of this study was to evaluate short-
term safety and tolerability of fingolimod in a real-world
population with relapsing multiple sclerosis, focusing on
cardiac safety during treatment initiation. Patients received
fingolimod 0.5 mg once daily for four months. Patients
excluded from the pivotal studies with certain pre-existing
cardiac conditions or baseline cardiac findings (PCCs), and
those receiving beta blockers (BBs) and/or calcium channel
blockers (CCBs), were eligible. Heart rate (HR) and elec-
trical conduction events were monitored using ambulatory
electrocardiography for at least 6 h after the first dose. Of
2,417 enrolled patients, 2,282 (94.4 %) completed the
study. Fingolimod initiation was associated with a tran-
sient, mostly asymptomatic decrease in HR. Bradycardia
adverse events occurred in 0.6 % of patients and were more
frequent in individuals receiving BBs/CCBs (3.3 %) than
in other patient subgroups (0.5–1.4 %); most events were
asymptomatic, and all patients recovered without
pharmacological intervention. In the 6 h post-dose, the
incidences of Mobitz type I second-degree atrioventricular
block (AVB) and 2:1 AVB were higher in patients with
PCCs (4.1 and 2.0 %, respectively) than in those without
(0.9 and 0.3 %, respectively); at pre-dose screening,
patients with PCCs had the same incidence of Mobitz type
I second-degree AVB (4.1 %) and a slightly lower inci-
dence of 2:1 AVB (0.7 %) than 6 h post-dose. All recorded
conduction abnormalities were asymptomatic. This study
adds to the evidence showing that cardiac effects during
fingolimod initiation remain consistent with those known
from previous, controlled studies, even if patients with
PCCs are included.
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Introduction
Fingolimod (FTY720) 0.5 mg once daily (GilenyaTM,
Novartis Pharma AG, Basel, Switzerland), a sphingosine
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1-phosphate receptor (S1PR) modulator [1], was the first
oral therapy approved for relapsing multiple sclerosis (MS)
[2–5].
Fingolimod has shown superior efficacy to intramuscu-
lar interferon b-1a in a 1-year study and to placebo in two
2-year phase 3 studies [6–8]. These pivotal studies also
established fingolimod as a treatment option with favorable
safety and tolerability.
Administration of the first dose of fingolimod is asso-
ciated with a decrease in heart rate (HR) and slowing of
atrioventricular (AV) conduction. This is a recognized
pharmacological effect of fingolimod, mediated by mod-
ulation of S1PR subtype 1 (S1P1) on atrial myocytes,
which is similar to vagal stimulation. The effect is typi-
cally transient, owing to the internalization/desensitization
of S1P1 [9], leading to functional antagonism rather than
agonism. The pivotal studies were designed to specifically
assess these effects in patients with relapsing MS and
showed that the first-dose effects of fingolimod on HR
and rhythm were transient (most resolved spontaneously
within 24 h), and that the symptoms of conduction delays
were uncommon (reported in \1 % of patients) and typ-
ically mild or moderate in severity [6–8]. However, as
these studies were conducted when fingolimod was an
experimental therapy, the patient criteria were cautious,
excluding patients with pre-existing cardiac conditions
and concomitant treatment with common HR-lowering
drugs.
Accordingly, this phase 3b, open-label, Fingolimod
Initiation and caRdiac Safety Trial (FIRST) evaluated the
short-term safety and tolerability of fingolimod 0.5 mg,
focusing in particular on cardiac safety during treatment
initiation, in a broader population of patients with relapsing
MS than previously investigated in the clinical develop-
ment program [6–8, 10]. It did not exclude patients with a
history of cardiac conditions (such as recurrent bradycar-
dia) or those receiving HR-lowering drugs [such as beta
blockers (BBs) or calcium channel blockers (CCBs)] to
establish whether the results of the pivotal studies remain
consistent in a population that more closely reflects the
patients who present in everyday clinical practice.
Methods
Study oversight
FIRST (ClinicalTrials.gov Identifier: NCT01497262) was
conducted in accordance with the International Conference
on Harmonisation Guidelines for Good Clinical Practice
[11] and the Declaration of Helsinki [12]. The protocol was
approved by each site’s independent Ethics Committee or
Institutional Review Board. All patients gave written
informed consent before any study-related procedures were
performed.
Participants
Patients were eligible for participation if they had a diag-
nosis of relapsing MS according to the 2005 revised
McDonald criteria [13], were aged 18–65 years, and had an
Expanded Disability Status Scale score of 0–6.5 [14]. In
contrast to the clinical development studies, participants
with controlled diabetes mellitus and the following pre-
existing cardiac conditions or baseline cardiac findings
(PCCs) were also eligible: recurrent symptomatic brady-
cardia, resting pulse rate of 45–54 beats per minute (bpm),
history of a positive tilt test for vasovagal syncope, and
history or presence of Mobitz type I second-degree AV
block (AVB) on the screening or baseline electrocardio-
gram (ECG). Concomitant medication with BBs and other
HR-lowering drugs was permitted. Patients were excluded
if they had previously participated in a fingolimod study or
had any cardiac disorder other than those stated above.
Other exclusion criteria were consistent with previous
fingolimod trials and have been described elsewhere
[6–8, 10].
Study design
FIRST was a 4-month, open-label, single-arm, phase 3b,
multicenter study that was conducted between May 2010
and October 2011 at 285 study centers across 23 countries.
All patients were treated with fingolimod 0.5 mg for
16 weeks. Patients initiated treatment either on-site (clinic
or office setting) or off-site.
Study procedures and endpoints
Screening
Patients entered a 1 to 2-week screening phase to determine
eligibility; screening included a 24-h ambulatory ECG
(AECG) recording and an ECG, both of which were ana-
lyzed by the central ECG vendor. The following safety
assessments were carried out: physical examination, vital
sign recordings, laboratory evaluations, pregnancy testing
for women, and ophthalmological examination and optical
coherence tomography performed by an ophthalmologist.
Before fingolimod first-dose administration
A pre-dose ECG was performed to establish whether
patients had PCCs; if they did, it was recommended that
those patients were monitored on-site rather than off-site.
However, any patient (with or without PCCs) could be
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monitored on-site if the local investigator considered this
appropriate.
Fingolimod treatment initiation
It was recommended that all patients take their first dose of
fingolimod before noon. All patients’ HRs and electrical
conduction events were monitored via AECG recording for
at least 6 h post-dose. Additionally, for individuals moni-
tored on-site, vital signs were recorded hourly for
approximately 6 h post-dose, and patients were asked to
inform the investigator about any cardiac symptoms or
other adverse events (AEs) that they experienced. Patients
initiating therapy off-site were instructed to contact the
investigator if any AEs occurred.
Patients monitored on-site were discharged after 6 h
providing that their HR was [80 % of the baseline value
and was not the lowest observed value, and that they had
no symptoms associated with decreased HR. If these dis-
charge criteria were not met, patients were monitored
hourly until the criteria were fulfilled. If an individual had
an HR \40 bpm, they were observed overnight on a ward/
monitoring unit. If a patient’s HR decreased more than
30 % from baseline at any time during the first 6-h moni-
toring period, or if they had any symptomatic event asso-
ciated with a reduction in HR during the first 24 h, the
second dose of fingolimod 0.5 mg was to be taken on-site
under first-dose monitoring conditions.
Open-label treatment phase
Safety assessments were performed at weeks 2, 8 and 16.
The AEs, serious AEs (SAEs), concomitant medication,
vital signs, hematology, blood chemistry, pregnancy test
results for women, and MS relapses were assessed at each
study time point. Ophthalmological examinations were
performed at 16 weeks. Patients who completed the
16-week treatment phase could enter an optional extension
study to receive continuous treatment with fingolimod
0.5 mg. Patients who did not enter the extension returned
for a follow-up visit 12 weeks after the last dose of study
drug for final safety assessments.
Endpoints
The primary objective of FIRST was to evaluate the
short-term safety and tolerability profile of fingolimod
0.5 mg in a broader population of patients with relapsing
forms of MS than previously studied with a focus on
cardiac safety. The variables used to evaluate the primary
objective were: AEs and SAEs; laboratory, vital sign and
first-dose AECG recording data; and ophthalmological
and skin assessments.
Statistical analyses
The incidence of AVBs and conduction abnormalities
recorded by the first-dose 6-h ECG, alanine aminotrans-
ferase elevations determined by liver function tests, and
macular edema diagnosis were selected for the consider-
ation of sample size calculation (see online resource 1).
Primary variables were summarized using descriptive sta-
tistics. For continuous variables, summary statistics inclu-
ded number, mean, standard deviation, and minimum and
Table 1 Patient demographic and baseline clinical characteristics,
previous treatment with DMTs and type of first-dose monitoring in
the overall population and subgroups (enrolled population)
Fingolimod 0.5 mg
(n = 2,417)
Female, n (%) 1,773 (73.4)





Duration of MS since first symptom, years,
mean ± SD
9.3 ± 6.9
Number of relapses in past year, mean ± SD 1.1 ± 1.1
EDSS score, mean ± SD 2.4 ± 1.5
History of macular edema, n (%) 2 (0.1)
History of uveitis, n (%) 25 (1.0)
History of optic neuritis, n (%) 1,022 (42.3)
Patients with diabetes mellitus, n (%) 26 (1.1)
Previously treated with DMTs, n (%) 2,054 (85)
Any interferon b 1,699 (70.3)
Other interferons 636 (26.3)




Other MS medications 123 (5.1)
Patients monitored on-site, n (%)a 1,221 (50.5)
Patients with PCCs, n (%) 296 (12.2)
Patients with PCCs who were monitored
on-site, n (%)
271 (11.2)
Patients receiving concomitant treatment
with BBs/CCBs, n (%)
120 (5.0)
Patients receiving concomitant treatment with
BBs/CCBs who were monitored
on-site, n (%)
78 (3.2)
BBs beta blockers, CCBs calcium channel blockers, DMT disease-
modifying therapy, EDSS Expanded Disability Status Scale, MS
multiple sclerosis, PCCs pre-existing cardiac conditions or baseline
cardiac findings, SD standard deviation
a Two of these patients did not receive study drug and were, there-
fore, not included in the safety set
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maximum values; frequencies and percentages were pro-
vided for categorical variables. The AECG data were
analyzed to determine the change in mean HR from the
equivalent hour at screening to 6 h post-dose. Vital signs
and laboratory data were summarized as mean change from
baseline. Supportive safety analyses were summarized for
the following subgroups: patients with PCCs (PCC group)
versus those who did not have pre-existing cardiac condi-
tions or baseline cardiac findings [non-PCC (NPCC)
group], patients co-medicated with BBs and/or CCBs (BB/
CCB group) versus those who were not (NBB/NCCB




Of 2,417 enrolled patients, 2,415 received at least one dose
of the study drug and were included in the safety set. A
total of 2,282 patients (94.4 %) completed, and 135 indi-
viduals (5.6 %) discontinued, the study, most commonly
owing to AEs (2.8 %), abnormal laboratory values (1.1 %),
or withdrawal of consent (0.5 %).
Baseline demographic and clinical characteristics
(Table 1) were consistent with a typical population of
patients with relapsing MS. Most participants (85 %) had
been previously treated with disease-modifying therapy
(Table 1). Approximately 50 % of patients were monitored
off-site.
Cardiac effects during treatment initiation
Adverse events and serious adverse events
Cardiac AEs were reported in 49/2,415 patients (2.0 %) in
the overall study population on days 1 and 2 after treatment
initiation; 14 of these patients were in the PCC or BB/CCB
subgroups (Table 2). Bradycardia was the most frequently
reported cardiac AE (15 patients, 0.6 %), with propor-
tionately more cases occurring in the BB/CCB group
(3.3 %) than in the other subgroups (0.5–1.4 %) (Table 2);
these cases were mostly asymptomatic and all patients
recovered without pharmacological intervention. Four
patients (0.2 %) discontinued fingolimod owing to a car-
diac AE [suspected angina pectoris (day 1 and day 33),
Mobitz type I second-degree AVB (day 1), and cardio-
vascular disorder (day 3)]; none of these patients had PCCs
or were co-medicated with BBs/CCBs.
During the 4-month study, six SAEs reported in five
patients were classified as cardiac disorders: angina pec-
toris, second-degree AVB, bradycardia, cardiac disorder,
cardiovascular disorder, and sinus bradycardia. None of the
patients with a cardiac SAE were in the PCC or BB/CCB
subgroups. All events manifested within 48 h of receiving
the first dose except for one that occurred 41 days post-
dose (reported as cardiovascular disorder with moderate
Table 2 Cardiac adverse events occurring in C1 patient on days 1 and 2 after administration of first dose of fingolimod 0.5 mg by subgroups
(safety set)










Total 49 (2.0) 42 (2.0) 7 (2.4) 42 (1.8) 7 (5.8)
Palpitations 14 (0.6) 14 (0.7) 0 (0.0) 14 (0.6) 0 (0.0)
Bradycardia 15 (0.6) 11 (0.5) 4 (1.4) 11 (0.5) 4 (3.3)
Tachycardia 2 (0.1) 1 (0.0) 1 (0.3) 2 (0.1) 0 (0.0)
Cardiovascular disorder 3 (0.1) 3 (0.1) 0 (0.0) 3 (0.1) 0 (0.0)
Angina pectoris 3 (0.1) 2 (0.1) 1 (0.3) 2 (0.1) 1 (0.8)
Second-degree AVB 5 (0.2) 5 (0.2) 0 (0.0) 5 (0.2) 0 (0.0)
Ventricular extra systoles 4 (0.2) 3 (0.1) 1 (0.3) 2 (0.1) 2 (1.7)
Ventricular tachycardia 1 (0.0) 1 (0.0) 0 (0.0) 1 (0.0) 0 (0.0)
Cardiac disorder 1 (0.0) 1 (0.0) 0 (0.0) 1 (0.0) 0 (0.0)
Sinus bradycardia 1 (0.0) 1 (0.0) 0 (0.0) 1 (0.0) 0 (0.0)
AVB 1 (0.0) 1 (0.0) 0 (0.0) 1 (0.0) 0 (0.0)
Safety set includes all patients who received at least one dose of fingolimod
Extra systoles, arrhythmia, first-degree AVB, left or right bundle branch block, cardiac asthma or left ventricular hypertrophy did not occur in
any patients
AVB atrioventricular block, BBs beta blockers, CCBs calcium channel blockers, PCCs pre-existing cardiac conditions or baseline cardiac findings
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symptoms of dizziness, hypotension and nausea). Two of
the cardiac SAEs (suspected, but not confirmed angina
pectoris and Mobitz type I second-degree AVB, which was
asymptomatic) resulted in study drug discontinuation. The
suspected case of angina pectoris was reported in a
30-year-old woman: the event was reported on treatment
initiation as mild in nature, occurred a few minutes after
treatment initiation, but reoccurred with subsequent dosing;
the event completely resolved upon treatment discontinu-
ation and without intervention. The case of second-degree
AVB was detected by Holter monitoring in a 24-year-old
woman following treatment initiation: the event was
asymptomatic, lasted for\3 s and was recorded as severe;
treatment was discontinued. The cases of bradycardia and
cardiac disorder detected on ECG were reported in a
23-year-old woman on day 2 who was diagnosed with a
urinary tract infection and a white blood cell count increase
the day before: the events were mild (cardiac disorder;
manifested as chest pain and difficulty in breathing and
micturition) or moderate (bradycardia) in severity and
resolved without intervention on the same day and in the
same timeframe as the infection while continuing fingoli-
mod therapy. The case of cardiovascular disorder reported
in a 40-year-old man on day 41 was manifest as circulation
problems (considered probably to be a migraine), dizzi-
ness, tinnitus, vertigo and vomiting, which were all mod-
erate in severity: hetastarch and metoclopramide were used
to treat the symptoms and the patient continued treatment
with fingolimod. The case of sinus bradycardia was
reported on day 1 after treatment initiation in a 26-year-old
man who had abnormal screening ECGs at day -17 (first-
degree AVB and ventricular premature beats) and baseline
(intraventricular conduction defect, first-degree AVB and
sinus bradycardia): the event was moderate in severity, had
resolved by the next day, did not require intervention, and
the patient continued fingolimod therapy.
Incidence of AV conduction abnormalities recorded
by AECG
For the overall population, the incidences of Mobitz type I
second-degree AVB and 2:1 AVB in the 6 h post-dose
were 1.3 and 0.5 %, respectively, compared with 0.5 and
0.1 %, in the 6 h pre-treatment. No patient developed
Mobitz type II second-degree AVB or complete AVB.
Mobitz type I second-degree AVB occurred approximately
five times more frequently in patients with PCCs than in
those without PCCs, both pre- and post-treatment initiation
(Table 3). Although rare overall, new-onset AVB post-
dose was detected twice as frequently in patients in the
PCC group (2 %) than in the NPCC group (0.9 %). No
AVBs were detected in the BB/CCB group, pre- or post-
treatment initiation.
Pulse rate
In the on-site population of 1,219 patients, the mean
baseline pulse rate of the PCC group (68.6 bpm) was lower
than that of the NPCC group (73.5 bpm). Patients in the
PCC group reached a mean nadir pulse rate at 4 h post-
dose compared with 5 h post-dose for patients in the NPCC
group (Fig. 1). The maximum mean change in pulse rate
was also smaller in the PCC group than in the NPCC group
[-6.5 (range -36.3 to 17.3) bpm and -7.4 (range -45.7 to
23.3) bpm, respectively]. Mean baseline pulse rate was
lower in the BB/CCB group (69.4 bpm) than in the NBB/
NCCB group (73.0 bpm). The BB/CCB group reached a
mean nadir pulse rate at 4 h post-dose compared with 5 h
post-dose for the NBB/NCCB group. The maximum
change in pulse rate from baseline was similar between the
BB/CCB and NBB/NCCB groups [-7.3 (range -36.3 to
10) bpm and -7.2 (range -45.7 to 23.3) bpm, respec-
tively]. Mean pulse rates for the on-site monitored patients
are provided in online resource 2. Mean pulse rates over
the 16-week treatment period were similar to pre-dose
readings (variation of \5 bpm above or below pre-dose
rates); a similar pattern was observed across subgroups.
Of the 1,219 on-site patients, 16 patients (1.3 %) had a
reduction in HR to \45 bpm during the 6-h post-dose
monitoring period. After 6 h, 40 patients (3.3 %) required
Table 3 Incidence of AVBs on AECG recording: 6 h pre-treatment
versus following administration of first dose of fingolimod 0.5 mg by













0 ( 12 (4.1) 0




18 (0.9) 12 (4.1) 0
2:1 AVB 7 (0.3) 6 (2.0) 0
Patients with events both
pre-dose and post-dose
0 ( 6 (2.0) 0
Patients with new post-dose
events
19 (0.9) 6 (2.0) 0
Safety set includes all patients who received at least one dose of
fingolimod
AECG ambulatory electrocardiogram, AVB atrioventricular block,
BBs beta blockers, CCBs calcium channel blockers, PCCs pre-exist-
ing cardiac conditions or baseline cardiac findings
a Some individuals had two types of second-degree AVB (Mobitz
type I and 2:1 AVB)
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extended monitoring. Of the 271 patients with PCCs who
were monitored on-site, 15 patients (5.5 %) required
extended monitoring. Of the 78 patients receiving BBs/
CCBs who were monitored on-site, three patients (3.8 %)
required extended monitoring. Most (31/40) patients who
required extended monitoring were discharged after 7 h
(i.e., after one additional hour of monitoring); this included
12 of the 15 patients with PCCs and all three patients
receiving BBs/CCBs.
None of the nine patients who required extended mon-
itoring beyond 7 h on day 1 discontinued fingolimod
treatment due to a first dose event or were kept in for
overnight monitoring. All nine patients were discharged on
day 1 after a maximum of 3 h of extended monitoring. In
eight of these patients, monitoring was extended on day 1
because the HR discharge criteria were not met (i.e., HR at
6 h post-dose was\80 % of the baseline pre-dose value or
was the lowest observed value). Symptomatic bradycardia
was reported in the remaining patient; this patient also did
not meet the HR discharge criteria and returned for mon-
itoring on day 2 before being discharged without extended
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Fig. 1 Hourly mean change in pulse rate from pre-dose sitting pulse
rate (a) and mean change in pulse rate across visits from pre-dose
sitting pulse rate (b) for patients who had/did not have pre-existing
cardiac conditions or baseline cardiac findings (PCCs), and hourly
mean change in pulse rate from pre-dose sitting pulse rate (c) and
mean change in pulse rate across visits from pre-dose sitting pulse
rate (d) for patients who were receiving/not receiving beta blockers/
calcium channel blockers (BBs/CCBs). bpm beats per minute, NBB/
NCCB not receiving BBs/CCBs, NPCC no PCCs
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required extended monitoring on day 1 because they did
not meet the HR discharge criteria, an asymptomatic sinus
bradycardia SAE was also reported on day 1 (details pro-
vided in the AE and SAE results section of this paper); the
patient was hospitalized for second-dose monitoring and
was discharged on day 2 without requiring intervention.
Heart rate on AECG at screening and after the first dose
(safety set)
The mean time to nadir hourly HR was similar in patients
with PCCs and those without (Fig. 2a). Similarly, the mean
time to nadir hourly HR was comparable between patients
receiving and not receiving BBs/CCBs (Fig. 2b). The
maximum, mean and median changes in HR were slightly
greater in the PCC group than in the NPCC group (Fig. 2c).
The maximum, mean and median changes in HR in the BB/
CCB group were smaller than in the NBB/NCCB group
(Fig. 2d).
Overall safety and tolerability
AEs and SAEs were reported in 75.3 % and 4.1 % of
patients, respectively; details are provided in online
resource 2. One death (suicide) occurred during the study
and was not considered by the investigator to be related to
the study drug. The most common AEs (reported in at least
5 % of patients) were nasopharyngitis, headache, lym-
phopenia, and fatigue. Results from dilated ophthalmos-
copy assessments, laboratory evaluations, and details of
other events of interest are provided in online resource 3.
Mean systolic/diastolic blood pressure increased from
120.1/77.3 mmHg at baseline to 122.3/78.8 mmHg at
month 2 and remained stable thereafter; over the 4-month
study period, the mean increase was 2.2 (standard deviation
[SD], 10.8)/1.3 (SD, 8.1) mmHg.
Discussion
Consistent with previous studies [7, 8, 10, 15], the first
dose of fingolimod was associated with a transient, mostly
asymptomatic, decrease in HR. A larger maximal change
in HR was observed with AECG monitoring in the whole
population than with pulse rate data from the patients
monitored on-site. The maximal change in pulse rate was
measured as a change from baseline immediately post-
dose in on-site patients who were sedentary. In contrast,
HR changes on AECG recordings were based on post-
dose hourly mean HR changes from the equivalent time
of day at screening. Different levels of physical activity
during screening, and after the first dose of fingolimod,
might account for the larger change in HR on AECG
recordings.
Although the occurrence of bradycardia was rare in the
overall study population, more cases of bradycardia were
observed in the BB/CCB group during the first two days of
treatment than in other subgroups. The lower baseline mean
pulse rate observed in the BB/CCB group than in the NBB/
NCCB group (as expected with these medications) may
have potentially predisposed these patients to bradycardia.
It has been shown previously in healthy volunteers that
atenolol in combination with fingolimod results in a 15 %
lower nadir HR than fingolimod alone [16]. Interestingly,
despite more cases of bradycardia in the BB/CCB subgroup,
the mean reduction in pulse rate and timing of recovery was
generally similar between patients in the BB/CCB and
NBB/NCCB groups. The majority of patients did not
require extended monitoring and were discharged after 6 h.
The overall incidence of AVBs following treatment
initiation was low. A small number of AVBs occurred pre-
treatment; emphasizing that AVBs can occur even without
treatment and may go unnoticed. Mobitz type I second-
degree AVBs and 2:1 AVBs occurred more frequently in
the PCC group than in the NPCC group, both pre-dose and
in the first 6 h post-dose. New-onset AVBs post-dose were
more common in the PCC than in the NPCC group,
although they were infrequent overall. Consistent with
previous findings, conduction abnormalities were asymp-
tomatic and no patients developed a Mobitz type II second-
degree AVB or complete AVB. No patients in the BB/CCB
group had any AVB detected during the 6-h pre- and post-
dose AECG monitoring; however, this subgroup was small.
No patients in the PCC or BB/CBB groups discontinued
the study drug owing to a cardiac AE.
This is the first fingolimod clinical study that has
extended eligibility to patients with PCCs. Overall, no new
safety findings were identified using fingolimod 0.5 mg in
this broader population of patients with MS compared with
previous fingolimod studies with more restrictive eligibility
criteria. The study findings confirm that cardiac effects
following the first dose of fingolimod are transient, mostly
asymptomatic, and observed in the first 6 h post-dose; this
is consistent with previous studies [7, 8, 15]. Our findings
further suggest that there is no increased risk of symp-
tomatic or serious cardiac events during treatment initiation
in patients with PCCs or in those receiving BBs/CCBs. A
recent study (of 317 patients) in clinical practice also found
that individuals using BBs or CCBs had uneventful first-
dose observations [17]. This notwithstanding, fingolimod is
not recommended for patients with a history of certain
cardiac conditions that were included in FIRST or for
patients who are receiving concurrent treatment with BBs/
CCBs [2, 18].
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PCC: mean (SD) = –25.0 (10.8), 
median (range) = –24 (–84 to 4)
NPCC: mean (SD) = –24.2 (11.0), 
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Time to nadir (hours)
BB/CCB: mean (SD) = –21.6 (10.0), 
median (range) = –21 (–49 to –3)
NBB/NCCB: mean (SD) = –24.4 (11.0), 
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3 4 5 6 7
Time to maximal change (hours)
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Overall, the types of AEs and SAEs, as well as the low
discontinuation rates observed in FIRST, were consistent
with those seen in previous phase 3 fingolimod studies [6–
8]. Specifically, the AEs of interest (macular edema, herpes
infections, and liver enzyme elevations) did not show an
increase over background rates observed in previous
studies.
Although FIRST included a broader population of
patients with MS than previously investigated and had a
large sample size, it had some limitations. FIRST had no
control group and the duration of the study was relatively
short compared with other phase 3 studies. However, the
aim of this study was to investigate early dosing with fin-
golimod, with a specific focus on HR and rhythm distur-
bances during treatment initiation. Owing to small and
uneven group sizes, inferential statistical testing was not
performed. Lastly, it should be acknowledged that only 26
patients with diabetes mellitus were included; therefore,
definite conclusions should not be drawn regarding the risk
of macular edema in this subpopulation.
FIRST extends our knowledge of the previously repor-
ted short-term safety and tolerability profile of fingolimod,
in relation to both first-dose effects and the first four
months of treatment, and includes a broader population of
patients with relapsing MS than previously evaluated in the
fingolimod development program. The results support the
use of fingolimod in patients with relapsing MS who are
more representative of those treated in everyday clinical
practice than the phase 3 populations.
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